Please note that NICE intends to formally start the appraisal in February 2024 and invite stakeholder submissions in April 2024. Timelines for both NICE guidance and licensing depend on data from the SUPERNOVA trial being available. However, the company will submit clinical data to NICE and the MHRA at the same time, with the aim of both organisations being able to reach decisions as close together as possible.